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Summary. Partial liquid ventilation (PLV) has been applied in various pulmonary diseases. We
describe the use of partial liquid ventilation as a lavage method following normal saline (NS)
lavage in an infant with pulmonary alveolar proteinosis (PAP) and severe hypoxemia. A 6 weeks
old 3.4 kg former 36 weeks gestation boy on supplemental oxygen was transferred to our NICU
with persistent tachypnea, dry cough, and increasing oxygen requirements. A lingular open lung
biopsy revealed PAP. He developed progressive respiratory failure requiring ventilatory support,
necessitating conventional NS lavage, followed by lung lavage with perflubron (LiquiVent; Alli-
ance Pharmaceutical Corp. and Hoechst Marion Roussel) while on venovenous extracorporeal
life support (ECLS). Lung lavage with NS and perflubron yielded minimal cloudy effluent. Gas
exchange and pulmonary function deteriorated following NS lavage and attempts to discontinue
ECLS were poorly tolerated. In contrast, tidal volume, PaO2, and pulmonary compliance in-
creased after PLV, while the (A-a) DO2 decreased to a point where ECLS was no longer required.
Once perflubron was added repeatedly to the ventilator circuit to correct for evaporation over the
4 days of PLV. Cardiovascular status remained stable for several days; however, eventually he
required reinitiation of ECLS and more mechanical ventilatory support with each trial off ECLS.
He was maintained on high pressures and FiO2 without any possibility to wean him from me-
chanical ventilation. Life support was withdrawn 1 month after admission. The survival from PAP
in infants remains dismal, even with total lung NS lavage. While both NS and perflubron lavage
in this patient were not effective in removing the proteinaceous alveolar debris, PLV following NS
lavage was associated with an improvement in gas exchange and lung compliance. Pediatr
Pulmonol. 1998; 26:283–286. © 1998 Wiley-Liss, Inc.
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INTRODUCTION
Pulmonary alveolar proteinosis is a rare disease of
unknown etiology, characterized by an abundant deposi-
tion of periodic acid-Schiff-positive proteinaceous mate-
rial in the alveoli.1 It is also a well-known cause of
chronic neonatal respiratory distress in which severe im-
pairment of gas exchange and pulmonary defenses
against organisms occurs. Whole lung lavage with nor-
mal saline in conjunction with extracorporeal life support
has been used successfully in symptomatic neonates and
children to improve oxygenation.2 Mortality remains
high and prognosis poor despite current aggressive man-
agement practices. Partial liquid ventilation has been
used with success in acute lung injury models. It has
never been used in a diffuse air space disease such as
pulmonary alveolar proteinosis. We experimentally ap-
plied partial liquid ventilation as a last resort in the treat-
ment of an infant in severe progressive respiratory failure
with atypical pulmonary alveolar proteinosis, unrespon-
sive to conventional therapies and we used perflubron as
an alternative lavage medium to normal saline in the
hope to improve gas exchange.
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CASE PRESENTATION
A 6-week-old 3.4 kg boy presented with persistent
tachypnea, dry cough, and increasing oxygen require-
ments. Past medical history revealed a former 36-weeks
gestation infant with a birth weight of 2.9 kg and RDS at
birth. He was treated with surfactant and was mechani-
cally ventilated for 1 week with subsequent supplemental
nasal cannula oxygen and rapid development of radio-
graphic changes indicative of BPD. He was discharged at
5 weeks of age on systemic steroids, diuretics, and oxy-
gen.
He was readmitted a week later and transferred to our
institution with tachypnea, dry cough, and increasing
oxygen requirement. Chest X-ray (Fig. 1) and high reso-
lution chest CT showed diffuse alveolar disease. Sweat
chloride was normal. Flexible bronchoscopy revealed
normal airways with scant secretions. Open lung biopsy
demonstrated a significant degree of pulmonary alveolar
proteinosis (Fig. 2). He developed a pneumothorax after
the lung biopsy. Adequate lung reexpansion followed
chest tube placement. He developed progressive respira-
tory failure necessitating mechanical ventilatory support.
His respiratory status deteriorated despite the use of ste-
roids, diuretics, and rhDNase (Pulmozymet, Genentech,
San Francisco, CA). Because of persistent respiratory
failure and increasing ventilatory support requirements,
total lung lavage with normal saline under venovenous
ECLS was carried out, which yielded minimal cloudy
effluent in which surfactant protein B was detected when
sent to a reference laboratory.3 Gas exchange and pul-
monary function deteriorated further following normal
saline lavage.
Because attempts to discontinue ECLS were poorly
tolerated, lung lavage and ventilation with perflubron
was instituted experimentally to improve oxygenation
and serve as an alternative lavage medium for removal of
proteinaceous material. The protocol, as part of a Phase
II trial of PLV in adults, children and neonates with acute
parenchymal lung injury, was reviewed and approved by
the Institutional Review Board. The trachea was reintu-
bated with an experimental polyurethane perflubron-
compatible endotracheal tube; baseline chest x-ray and
airway examination with bronchoscopy were performed.
Time-cycled, pressure-controlled ventilation on a VIP
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Fig. 1. PA chest X-ray of the infant at initial presentation, dem-
onstrating diffuse alveolar infiltration.
Fig. 2. Histological findings of lingular lobe biopsy showing
alveoli filled with dense, PAS-positive homogeneous material,
mild hyperplasia of the alveolar epithelium, and absence of in-
flammation and fibrosis, diagnostic for pulmonary alveolar pro-
teinosis. (PAS stain; original magnification 20×).
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Bird ventilator was used at settings which included PIP
of 25–30 cm H2O, PEEP4 5 cm H2O, respiratory rate
4 30 breaths/min; I:E ratio4 1:1, and FiO2 4 1.0.
Perflubron was administered via the endotracheal tube in
5 ml/kg aliquots over 5 to 15-min periods for a total of 20
ml/kg, a dose to approximate functional residual capacity
(FRC). At this point, a meniscus was present within the
endotracheal tube at the level of the sternum when the
infant was transiently disconnected from the ventilator.
Since a minimal amount of alveolar debris was removed
at FRC, the lungs were lavaged with an additional 10
cc/kg of perflubron, but no additional debris was evacu-
ated. Supplemental doses, ranging from 10 cc/kg to 20
cc/kg, were administered to maintain lung filling to FRC
with perflubron (Fig. 3). The need for refilling was based
on radiographic evidence of perflubron evaporation.
Since we expected significant mucus plugging, frequent
suctioning was performed. Surprisingly, a very small
amount of plugging was evident during the treatment
period.
The total lung lavage with perflubron or normal saline
yielded minimal debris. No quantification of the protein-
aceous material from either the saline or the perflubron
lavage was obtained, given the minimal yield. Further-
more, the initial poor yield made it difficult to determine
whether the amount of protein diminished on serial la-
vage aliquots during either conventional saline or experi-
mental perflubron lavage.
As the perflubron evaporated, there was a correspond-
ing increase in the need for ventilatory support suggested
by decreased tidal volumes, PaO2, and increased FiO2
requirements. Similarly, with each filling there was an
increase in the tidal volume and PaO2. The (A-a) DO2
decreased, implying an improvement in cardiac output,
and an increase in pulmonary compliance during partial
liquid ventilation. Examples of the responses to dosing
are given in Figure 4.
A pneumothorax developed post-thoracotomy and was
evacuated successfully by chest tube prior to the instil-
lation of perflubron; no extravasation of perflubron into
the chest cavity was noted during partial liquid ventila-
tion. The patient tolerated administration of perflubron
without evidence of hemodynamic compromise. No
complications occurred during or following the period of
partial liquid ventilation. After a total of 4 days of PLV
in which gas exchange was supported effectively, the
infant was again placed on ECLS for pulmonary support.
He was slowly weaned to ventilatory support with high
airway pressures and FiO2. Two days later, all support
was withdrawn given the overall poor response to
therapy and prognosis from irreversible lung disease.
DISCUSSION
Pulmonary alveolar proteinosis in the newborn period
remains a disease of high mortality and extremely poor
prognosis. As in other acute parenchymal lung diseases,
high levels of airway pressure and FiO2 during conven-
tional mechanical ventilation did not improve recruit-
ment of noncompliant lungs and were unable to over-
come the abnormal alveolar surface tension inherent in
this type of respiratory insufficiency. Total lung lavage
with normal saline in combination with ECLS, especially
in newborns and children, can successfully remove the
offending debris deposited at the alveolar level.2 How-
ever, normal saline is a poor respiratory medium and
possesses fluid properties that potentiate removal of sur-
factant and, hence, further impairs lung mechanics.4
Liquid ventilation with perflubron has been used suc-
cessfully in animal models of neonatal respiratory dis-
tress syndrome,5 ARDS,6 as a lavage medium in meco-
ium aspiration syndrome,7 as a contrast material in im-
aging studies,8 and as a potential pharmaceutical or
Fig. 3. AP chest x-ray demonstrating the usual appearance of
the radiopaque perflubron-filled lungs.
Fig. 4. Arterial PO 2, PCO2, and tidal volume responses to per-
flubron filling.
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biological delivery agent.9 In addition, partial liquid ven-
tilation has been applied in adults, children, and new-
borns with respiratory insufficiency.10–15 We describe a
potential novel adjunct therapy, using PLV in the treat-
ment of severe pulmonary alveolar proteinosis.
Perflubron has many advantages as a lavage medium.
It has excellent oxygen and carbon dioxide carrying ca-
pacity and allows for homogeneous ventilation and im-
proved recruitment of injured lungs.16,17It is insoluble in
all biologically known media and does not wash out sur-
factant in the process of ventilation.18 Partial liquid ven-
tilation may be used to improve pulmonary function and
tidal volume following whole lung saline lavage, as was
demonstrated in this patient. Lavage with saline followed
by perflubron may be most effective. Although it clearly
improves oxygenation compared to normal saline, per-
flubron is limited in that its immiscibility does not allow
for the proteinaceous debris to mix, making perflubron
potentially less desirable for evacuation of alveolar de-
bris.
Our patient had histologically proven pulmonary al-
veolar proteinosis, although his presentation was atypi-
cal. Survival was not improved. While a case report of
one patient with equivocal response provides limited in-
formation, we believe that perfluorocarbon as a lavage
medium in this heterogeneous disease remains a potential
adjunctive therapy in the treatment of PAP because it can
function both as a lavage medium and as a means for
gentle oxygenation and ventilation of the injured lung
following an initial normal saline bronchopulmonary la-
vage. Because of perflubron’s major limitation as a de-
bris-evacuating lavage medium, further experience must
be gained by evaluation of more patients with PAP in
severe respiratory failure before its role in the therapy of
pulmonary alveolar proteinosis can be clarified.
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